Calendario de vacunaciones de la Asociación Española de Pediatríarecomendaciones 2013
- David Moreno Pérez
- Francisco José Álvarez García
- Javier Arístegui Fernández
- Francisco Barrio Corrales
- María José Cilleruelo Ortega
- Josep María Corretger Rauet
- José González-Hachero
- Teresa Hernández-Sampelayo Matos
- Manuel Merino Moína
- Luis Ortigosa del Castillo
- Jesús Ruiz Contreras
ISSN: 1695-4033, 1696-4608
Año de publicación: 2013
Volumen: 78
Número: 1
Páginas: 59
Tipo: Artículo
Otras publicaciones en: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )
Resumen
Abstract The Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP) updates the immunisation schedule every year, taking into account epidemiological data as well as evidence on the safety, effectiveness and ef?ciency of vaccines. The present schedule includes levels ofrecommendation. We have graded as routine vaccinations those thattheCAV-AEP consider all children should receive; as recommended those that ?t the pro?le for universal childhood immunisation and would ideally be given to all children, but that can be prioritised according to the resources available fortheir public funding; and as risk group vaccinations those that speci?cally target individuals in situations of risk. Immunisation schedules tend to be dynamic and adaptable to ongoing epidemiological changes.Nevertheless, the achievement of a uni?ed immunisation schedule in all regions of Spain is a top priority for the CAV-AEP. Based on the latest epidemiologicaltrends, CAV-AEP follows the innovations proposed in the last year�s schedule, such as the administration of the ?rst dose of the MMR and the varicella vaccines at age 12 months and the second dose at age 2-3 years, as well as the administration of the Tdap vaccine at age 4-6 years, always followed by another dose at 11-14 years of age, preferably at 11-12 years. The CAV-AEP believes thatthe coverage of vaccination against human papillomavirus in girls aged 11-14 years, preferably at 11-12 years, must increase. It reasserts its recommendation to include vaccination against pneumococcal disease in the routine immunisation schedule. Universal vaccination against varicella in the second year of life is an effective strategy and therefore a desirable objective. Vaccination againstrotavirus is recommended in all infants due to the morbidity and elevated healthcare burden ofthe virus.TheCommittee stresses the need to vaccinate population groups considered at risk against in?uenza and hepatitis A. Finally, it emphasizes the need to bring incomplete vaccinations up to date following the catch-up immunisation schedule.